MOTS-c: The Mitochondrial-Derived Longevity Peptide

MOTS-c is a small peptide encoded by your mitochondrial DNA that signals to muscle and liver cells to use glucose and fat more efficiently. In mice it improves insulin sensitivity, protects against diet-induced weight gain and improves exercise capacity in older animals, but human evidence is still early and MOTS-c is not FDA-approved. It is a scientifically interesting molecule, not a proven longevity treatment.

Three linked problems behind many chronic diseases

Much of what I see in internal medicine traces back to three overlapping problems:

• Insulin resistance. Muscle, liver and fat cells respond less to insulin, so the body needs more insulin to keep glucose normal. Over years, this can progress to prediabetes, type 2 diabetes, fatty liver disease and higher cardiovascular risk.
• Chronic low-grade inflammation. Persistent activation of inflammatory signaling, with cytokines such as TNF-alpha and IL-6, contributes to vascular disease and to the general wear of aging.
• Declining mitochondrial function. Mitochondria produce most of the cell's usable energy (ATP). With age, inactivity and metabolic disease, their number and efficiency tend to fall.

These three feed one another. They are not the only causes of disease, but they are common threads in diabetes, heart disease and age-related decline. That is why a molecule that sits at the intersection of mitochondria and metabolism has attracted so much attention. You can read more about the broader topic in the role of mitochondrial health in aging.

What MOTS-c is and how it works

MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA type-c." It is a 16-amino-acid peptide, and what makes it unusual is where it comes from: it is encoded within the mitochondrial genome, not the nuclear DNA that codes for most proteins. Researchers describe it as a "mitochondrial-derived peptide," a messenger that lets mitochondria communicate with the rest of the cell and, through the bloodstream, with other tissues.

In laboratory studies, MOTS-c:

• Activates AMPK, the cell's main energy sensor, which shifts metabolism toward glucose uptake and fat oxidation.
• Increases glucose uptake in skeletal muscle, improving insulin sensitivity in animal models.
• Moves to the nucleus under metabolic stress, where it appears to influence genes involved in stress responses.
• Declines with age in some tissues and in circulation, based on animal and human measurements.

What the evidence shows on MOTS-c

The foundational study, published in Cell Metabolism in 2015, showed that MOTS-c treatment prevented diet-induced obesity and insulin resistance in mice fed a high-fat diet. A 2021 study in Nature Communications found that MOTS-c levels rise in human skeletal muscle and blood during exercise, and that treating older mice with MOTS-c improved their physical capacity.

Those are genuinely interesting findings. But it is important to be precise about what they do and do not show:

• Animal data are the core of the evidence. Mouse results on insulin sensitivity, weight and endurance have not been confirmed in controlled human trials.
• Human data are mostly observational. We know exercise raises natural MOTS-c, and some genetic variants in the MOTS-c region have been associated with metabolic traits in specific populations. That is not the same as showing that giving MOTS-c helps people.
• Early drug development has not produced an approved product. A modified MOTS-c analog was tested in early-phase human studies by a biotech company, but it has not progressed to approval.
• Some claims go well beyond the data. You will see online claims that MOTS-c treats fatty liver, heart disease or even cancer. The evidence for those claims is limited to animal or cell studies, and I would not describe MOTS-c as treating any human disease.

MOTS-c, metformin and SS-31: putting it in context

MOTS-c is often compared with metformin because both activate AMPK. Metformin, however, has decades of human safety and outcome data in type 2 diabetes. Whether metformin extends healthy lifespan in people without diabetes is unproven, and it can lower vitamin B12 over time, so it deserves monitoring like any medication. What we cannot say is that MOTS-c is "better" than metformin; no head-to-head human data exist. If both were ever used together, their glucose-lowering effects could add up, which matters for anyone on diabetes medications.

MOTS-c is also discussed alongside SS-31 (elamipretide), a peptide that binds the inner mitochondrial membrane. Elamipretide received FDA approval in 2025, but only for Barth syndrome, a rare genetic disorder. Online protocols that sequence MOTS-c and SS-31 in a particular order are speculation; no clinical trial has tested such a sequence.

Regulatory status and safety

Because human safety data are limited, caution is warranted in:

• Pregnancy and breastfeeding (no data)
• Active cancer, where the effects of mitochondrial signaling are unclear
• Diabetes treated with insulin or sulfonylureas, because of possible additive glucose lowering
• Primary mitochondrial disease, which needs specialist input

Any discussion of dosing is individualized and happens only after evaluation and labs. I do not recommend buying "research" MOTS-c online; product identity and purity are unverified. More details are summarized in our peptide library entry for MOTS-c.

What actually moves the same pathways today

The pathways MOTS-c acts on, AMPK activation, glucose uptake in muscle and mitochondrial biogenesis, are the same ones that respond strongly to things we already know work:

• Aerobic training, including steady Zone 2 cardio, which naturally raises MOTS-c levels
• Resistance training, which improves muscle glucose uptake
• Adequate sleep and weight management, which improve insulin sensitivity
• Treating insulin resistance directly when it is present, with evidence-based medications where appropriate

At Laeeq M.D., I start with labs such as fasting glucose, insulin, HbA1c, lipids and liver enzymes, to see where someone's metabolism actually stands. Those numbers guide the plan, and they are what we would monitor if any additional therapy were ever considered.

Sources

• Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/
• FDA Panel Backs 6 Peptides for Compounding. AJMC, 2026. https://ajmc.com/view/fda-panel-backs-6-peptides-for-compounding

Book a Consultation

If you are curious about MOTS-c or about improving your metabolic health more broadly, start with an evaluation. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in Reston, VA, where we review your labs, history and goals before discussing any therapy.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.